Sceptridium Ternatum For the Treatment of Pulmonary Arterial Hypertension in Rats with Pulmonary Heart

OBJECTIVE To observe the effect of Sceptridium Ternatum on pulmonary arterial hypertension in rats with pulmonary heart disease. METHODS All of 120 SD rats were randomly divided into control, model, sildenafil, Sceptridium Ternatum low-dose, middle-dose and high-dose drug groups, 20 rats in each group. The animal model were established by intraperitoneally injecting moncrotaline of 60 mg·kg^-1. Rats in control and model groups were given saline by gavage for 21 d. The mean right ventricular pressure(mRVP), mean pulmonary arterial pressure(mPAP), and max RVP were measured by using right cardiac catheterization. The rats were then sacrificed for determination of lung wet weight(WW) and the weight of right ventricule(RV) and left ventricule pus septum(LV+S). Lung index(LI) and right ventricular hypertrophy index(RVHI) were calculated. RESULTS The mRVP, mRAP, max RVP in model group were higher than those of the control group( P <0.001), and those parameters in the middle- and high-dose drug groups were lower than those of the model group( P <0.001-0.05). The RV, LV+S, WW, RVHI and LI in the high-dose drug group were smaller than those of the model group( P <0.001-0.01). CONCLUSION Sceptridium Ternatum may have some effect on pulmonary arterial hypertension induced by monocrotaine in rats.